Firms

Kaya VC

Prague, CZ

kaya.vc

signal.nfx.com

goldi.ai

KAYA is an early-stage VC fund with roots in CEE, investing in intrepid founders across Europe since 2010.

Founded: —
Type: Venture capital

Funds1

KAYA Fund V2025-06-252025-06-25—
NEARLYEUR70mFIRSTCLOSE, noexactamount/finalclose. OfficialundatedUSDsymbol85mcurrentfund,500mAUM and1–3mticketcurrency/vehicleunresolved notassumedFundVfinal.

Team

Jakub Jurovych Kaya VC, Venture Partner	—— – —
Julie Hucikova Kaya VC, Finance & Operations	—— – —
Juraj Masar Kaya VC, Venture Partner	—— – —
Karel Zheng Kaya VC, General Partner	—— – —
Klaudia Kristofova Kaya VC, Finance & Operations	—— – —
Martin Rajcan Kaya VC, General Partner	—— – —
Martin Schmid Kaya VC, Venture Partner	—— – —
Michal Valko Kaya VC, Venture Partner	—— – —
Pavel Mucha Kaya VC, Partner	—— – —
Tereza Mullerova Kaya VC, Office Manager	—— – —
Tomas Obrtac Kaya VC, General Partner	—— – —
Tomas Pacinda Kaya VC, General Partner	—— – —
Tomáš Čupr Kaya VC, Venture Partner	—— – —
Vaclav Ryslink Kaya VC, Investor	—— – —
Vojtech Tomsu Kaya VC, Analyst	—— – —

Investments

team@apexlogos.ai3 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund size, current mandate and stages | Evidence | Amount / status | Date and interpretation | |---|---|---| | [Official homepage](https://www.kaya.vc/) | $85m “Current Fund”; $500m “AUM Total”; $1–3m ticket | Undated, accessed 2026-10-06. Fund name, vintage, currency expansion beyond the dollar symbol, and legal final-close status are not stated. AUM and tickets are distinct from individual fund commitments. | | [Official news page](https://www.kaya.vc/news), linking [Tech Funding News announcement](https://techfundingnews.com/from-prague-to-the-world-meet-kaya-the-quiet-force-behind-central-europes-startup-unicorns-just-closed-a-e70m-fund/) | Nearly €70m raised at **first close of fifth fund** | 2025-06-25. Intended to support about 25 companies from pre-seed to Series A. The article headline's “closed” wording must not be converted into a verified final close. | The current [official homepage](https://www.kaya.vc/) states a CEE founder focus, pre-seed through scale, while the stage metric reads pre-seed/seed. This supports **current initial-entry focus: pre-seed and seed**, with broader continuing support. The 2025 fund announcement describes pre-seed through Series A. Historical Series A and later participation does not prove an unrestricted later-stage new-investment mandate. The same homepage says founded 2011, whereas Adex and the 2025 reporting say 2010/originally Enern Investments; retain this founding-date discrepancy for review. Searches for newer/final Fund V closes through 2026 did not establish a dated final-close announcement. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | KAYA Fund V | Undisclosed / unverified | 2025-06-25 |
team@apexlogos.ai4 hours ago
Match research 2026-10-06 / KayaVC / sha256:d3dcd9c97cb02946ae3a124853b1cadf759bcfb8ebe037e74b8fe868ee610072 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. | **Theorema** | AI systems for scientific R&D and causal disease models/target identification. Scientific AI deep-tech candidate; stronger than generic productivity AI, but technical validation of proprietary models was not independently audited. | [Official company team/about page](https://www.theorema.ai/about) lists KAYA VC as backer; [official product site](https://www.theorema.ai/) describes causal disease modeling. [Vestbee, 2026-03-31](https://www.vestbee.com/insights/articles/theorema-secures-2-85-m) reports €2.85m (CZK70m) pre-seed with KAYA VC among participants. [KAYA partner Martin Rajcan's April 2026 article](https://medium.com/kayavc/the-rise-of-biotech-in-cee-59520991ca18) also explicitly identifies Sensible and Theorema as companies working with KAYA. | E2B is a verified investment in AI-agent cloud infrastructure: the [company-issued PRNewswire announcement, 2025-07-28](https://www.prnewswire.com/news-releases/e2b-raises-a-21m-series-a-to-offer-cloud-for-ai-agents-to-fortune-100-302514540.html) names Kaya in its $21m Series A. It is relevant technical infrastructure but has weaker intrinsic science/hardware evidence than the companies above. Ordinary fintech, grocery marketplaces, design tooling and workflow SaaS in the baseline are not automatically counted as deep tech. ## Neurotech and adjacent investments **No verified neurotech investment found in the sources checked.** The searches covered the saved portfolio, KAYA official portfolio and AI paper, scientific portfolio company sites, and targeted KAYA/neurotech searches. This is a bounded finding, not proof the firm has never invested in neurotechnology. **Upheal** is a verified **mental-health software investment**, not direct neurotech. Its [official pre-seed announcement](https://www.upheal.io/au/blog/upheal-raises-1-05m-and-launches-the-first-ai-powered-platform-for-mental-health-professionals) names KAYA VC as lead of a $1.05m pre-seed round (page date not reliably established; accessed 2026-10-06). The [company's Series A post](https://www.linkedin.com/posts/upheal_seriesafunding-fundingannouncement-technews-activity-7262811549738639360-_-ry) names KAYA VC alongside Credo and Headline in a $10m Series A; November 2024 timing appears in contemporaneous financing coverage. Its AI documentation and therapy-session support do not measure, stimulate or interface with the nervous system. Theorema's disease models and Sensible's therapeutic production platform are not evidence of neural-specific investments. Cardiomatics records heart signals; NuvoAir concerns respiratory health. ## Conflicts, gaps and later Adex review 1. Capture current website's $85m current-fund, $500m AUM and $1–3m ticket metrics with access date. Keep them separate from the dated nearly €70m Fund V **first close**. Obtain legal fund name, currency and final-close confirmation before treating $85m as final Fund V size. 2. Resolve 2010 versus 2011 foundation date. The Enern predecessor relationship supports continuity, but some legal vehicles differ; do not confuse portfolio SPVs with standalone unrelated investor firms. 3. Add verified Allonic and Sensible investment leads if absent from current Adex after later authorized review. Direct portfolio/official investee evidence confirms attribution; KAYA check amounts are unavailable. 4. Resolve Yoneda financing amount/date differences before editing round data. Firm investment is well supported by KAYA's own paper; snapshot's March date is not corroborated here. 5. Cardiomatics headline financing includes non-equity support in reporting. Do not store the full headline sum as unqualified equity financing. 6. Artificial Agency's snapshot $12m financing, company $16m cumulative funding and legal-adviser $17m seed figure need currency/round reconciliation. Its investment attribution is secure. 7. New Sensible reporting on 2026-10-06 includes [e15 coverage](https://www.e15.cz/byznys/fond-spojeny-s-ceskym-zbrojarem-financuje-prekvapivy-obor-vstupuje-do-zavodu-o-lecbu-rakoviny-1436317) naming Kaya VC and Tech Horizons, while [Startup.eu](https://www.startup.eu/investments/sensible-biotechnologies-47-m-series-a-10-2026) reports $47m Series A and [Axios](https://www.axios.com/newsletters/axios-pro-rata-39a292f6-edf2-4429-b1d0-e562da2ba819) reports $27m Series A plus up to $20m non-dilutive funding. These may describe combined equity/grant totals; no definitive round reconciliation was made. The official older investor evidence remains sufficient for firm attribution. 8. Inspect SuperNova/Supernova.io duplication in baseline. Partner/scout involvement in Artificial Agency is supported alongside direct KAYA involvement; do not infer that every partner's past personal investment belongs to this firm. 9. Upheal aggregators sometimes identify “Kaya Ventures” in California despite company sources explicitly naming KAYA VC. Prefer the primary firm attribution and avoid identity merges. Research-only deliverable. No MCP Patch, database update, commit, or unrelated workspace changes were performed.
team@apexlogos.ai4 hours ago
Match research 2026-10-06 / KayaVC / sha256:d3dcd9c97cb02946ae3a124853b1cadf759bcfb8ebe037e74b8fe868ee610072 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # KAYA / Kaya VC — firm research - **Exact ID:** `KayaVC` - **Adex page:** https://adex.page/firms/KayaVC - **Official website:** https://www.kaya.vc/ - **Research/access date:** 2026-10-06 - **Status:** Complete research review; no Adex or database changes made. KAYA is a Prague/CEE-rooted early-stage investor with verified investments in robotics manufacturing, chemical reaction automation, synthetic biology, scientific AI and cardiac diagnostics. Its current site reports a **$85m current fund**, **$500m total AUM**, and **$1–3m tickets**. A dated 2025 announcement separately establishes a **nearly €70m first close of Fund V**. The relationship between these figures is not explicitly documented. No verified neurotech investment found in the sources checked. ## Starting evidence: Adex and NFX Signal The saved exact-ID MCP Search snapshot, `data/research/_sources/KayaVC.adex.json`, retrieved 2026-10-06, describes an early-stage European investor with CEE roots, active since 2010, lists Prague, and supplies the official site plus https://signal.nfx.com/firms/kaya-vc. Its investor profile has no populated check minimum, maximum or sweet spot. It contains 24 investment participations, including YonedaLabs, ArtificialAgency, Cardiomatics, E2B, JutroMedical, Nuvoair, Theorema and two apparent Supernova identity variants (`SuperNova` and `Supernova.io`). These records are leads, not independent corroboration. The NFX Signal firm URL was opened directly on 2026-10-06 and returned an Internal Error through the browser tool. Targeted Signal searches for KAYA, Martin Rajcan and Tomas Pacinda did not expose a usable matching profile. No Signal stage, check or fund-size claims could therefore be verified. Search results for Baturay Kaya/Earlybird, Kaya Founders in the Philippines, and California-based Kaya Ventures are different identities and were excluded. ## Fund size, current mandate and stages | Evidence | Amount / status | Date and interpretation | |---|---|---| | [Official homepage](https://www.kaya.vc/) | $85m “Current Fund”; $500m “AUM Total”; $1–3m ticket | Undated, accessed 2026-10-06. Fund name, vintage, currency expansion beyond the dollar symbol, and legal final-close status are not stated. AUM and tickets are distinct from individual fund commitments. | | [Official news page](https://www.kaya.vc/news), linking [Tech Funding News announcement](https://techfundingnews.com/from-prague-to-the-world-meet-kaya-the-quiet-force-behind-central-europes-startup-unicorns-just-closed-a-e70m-fund/) | Nearly €70m raised at **first close of fifth fund** | 2025-06-25. Intended to support about 25 companies from pre-seed to Series A. The article headline's “closed” wording must not be converted into a verified final close. | The current [official homepage](https://www.kaya.vc/) states a CEE founder focus, pre-seed through scale, while the stage metric reads pre-seed/seed. This supports **current initial-entry focus: pre-seed and seed**, with broader continuing support. The 2025 fund announcement describes pre-seed through Series A. Historical Series A and later participation does not prove an unrestricted later-stage new-investment mandate. The same homepage says founded 2011, whereas Adex and the 2025 reporting say 2010/originally Enern Investments; retain this founding-date discrepancy for review. Searches for newer/final Fund V closes through 2026 did not establish a dated final-close announcement. ## Named previous deep-tech investments Classification below is a research judgment based on technology. Round amounts are company financing totals, not KAYA check sizes. All sources accessed 2026-10-06. | Company | Technology and classification | Verified firm attribution / dated financing evidence | |---|---|---| | **Allonic** | Hardware/robotics manufacturing: automated 3D tissue braiding forms compliant robotic bodies, integrating fibers, actuators and tendons. “Tissue” here describes robot structure, not human biological tissue. Strong deep-tech fit. | Listed directly in [KAYA official portfolio](https://www.kaya.vc/portfolio). [Allonic official site](https://allonic.co/) supports manufacturing technology. [Vestbee, 2026-02-10](https://www.vestbee.com/insights/articles/allonic-secures-7-2-m) reports $7.2m pre-seed led by Visionaries Club; [Nordic9](https://nordic9.com/news/allonic-raised-72m-in-pre-seed-funding-with-day-one-capital-strt-prototype-capital/) lists Kaya VC among round investors but displays 2026-01-10, conflicting with February coverage. Firm investment verified; exact KAYA round/date should be confirmed before recording transaction detail. | | **Yoneda Labs** | Chemical reaction optimization using high-throughput automated experimentation and a proprietary dataset/model. Deep tech at chemistry/robotics/AI intersection. | [KAYA AI Opportunity Paper](https://newsletter.kaya.vc/content/files/2024/10/KAYA-AI-Opportunity-Paper.pdf), hosted October 2024, explicitly attributes an investment and describes its robot-generated chemistry dataset. [Official Yoneda site](https://www.yonedalabs.com/) supports current experimental chemistry services. [KAYA newsletter, 2024-06-12](https://newsletter.kaya.vc/ceefarers-jun-2024/) lists Kaya VC among investors with $4.6m; this is a financing claim, not a verified individual KAYA check. Exact round timing is unresolved: snapshot says 2024-03-25, newsletter summarizes May, and [CB Insights](https://www.cbinsights.com/company/yoneda-labs/financials) associates Kaya with a separate June 5 seed entry. | | **Sensible Biotechnologies** | Synthetic biology platform producing mRNA in living cells, with computational design and biomanufacturing process development. Strong deep-tech fit; general therapeutics infrastructure rather than direct neurotech. | [Official Sensible announcement, 2025-06-12](https://www.sensible.bio/press-release/sensible-biotechnologies-teams-up-with-nvidia-to-develop-computational-engine-for-cell-based-mrna-therapeutics-design) names Kaya VC among investors and says company had raised more than $13m. [KAYA paper](https://newsletter.kaya.vc/content/files/2024/10/KAYA-AI-Opportunity-Paper.pdf) also explicitly confirms investment. The announcement was readable through the search index; direct open returned Internal Error. This establishes attribution, not a single $13m round or KAYA amount. Recent October 2026 fundraising numbers conflict across coverage; see gaps below. | | **Artificial Agency** | Proprietary generative behavior engine incorporating runtime AI decision-making into games; a defensible research/model engine rather than ordinary SaaS. Broad AI deep-tech interpretation. | Company-issued [GlobeNewswire release, 2024-07-18](https://www.globenewswire.com/news-release/2024/07/18/2915134/0/en/Artificial-Agency-Launches-Out-of-Stealth-with-16M-USD-in-Funding-to-Bring-Generative-Behavior-to-Gaming.html) names Kaya and reports **$16m total funding**. [KAYA paper](https://newsletter.kaya.vc/content/files/2024/10/KAYA-AI-Opportunity-Paper.pdf) independently gives direct firm attribution alongside scout Martin Schmid. Legal adviser [Osler, 2024-07-18](https://www.osler.com/en/about-us/representative-work/artificial-agency/) describes follow-on support from Kaya and a $17m seed financing, with currency unspecified in extracted text. Keep amount distinctions unresolved instead of overwriting snapshot's $12m round using the $16m cumulative number. | | **Cardiomatics** | Clinically applied ECG interpretation AI, combining signal analysis and regulated diagnostic software. Medical deep-tech boundary case; cardiac electrical signals are not neural recordings. | [Official company announcement, 2021-08-25](https://cardiomatics.com/cardiomatics-raises-3-2-million-in-seed-funding/) explicitly welcomes Kaya VC as investor and names Pavel Mucha as board member. The [CVCA 2021 activity report](https://cvca.cz/wp-content/uploads/2022/06/CVCA-Activity-Report-2021.pdf), published 2022, identifies a Kaya-led August 2021 seed financing and ECG AI technology. The official headline gives $3.2m; finance databases distinguish $2.2m equity plus grant support, so review the capital composition before entering an equity round amount. |
team@apexlogos.ai22 days ago
MATCH

€2M2026-03-31	Theorema	Kaya VC
$—2025-12-16	Jutro Medical	Kaya VC
$9M2025-09-30	Supernova.io	Taiwania Capital, Y Combinator, EQT Ventures, Kaya VC, Credo Ventures, J&T Ventures, Reflex Capital, Wing Venture Capital
$21M2025-07-28	E2B	Decibel, Kaya VC
$—2025-07-01	TopK	Earlybird Venture Capital, Kaya VC
$—2025-03-19	Jutro Medical	Kaya VC
$4M2024-03-25	YonedaLabs	Khosla Ventures, Kaya VC, 468 Capital
$10M2024-01-25	Better Stack	Creandum, Kaya VC, Angeles Investors
$2M2024	TrueClaim	Y Combinator, Kaya VC, Rebel Fund, Orange Collective, Explorer Investments, Liquidity Capital
$4M2022-11-16	Supernova.io	Credo Ventures, Wing Venture Capital, Kaya VC
$18M2022-07-21	Better Stack	Creandum, Kaya VC, Credo Ventures, K5 Global, Susa Ventures
$10M2022-02-22	Sanzo	Kaya VC
$2M2022	Healee	Kaya VC
$—2021-08-25	Cardiomatics	Kaya VC
$12M2021-06-22	Nuvoair	Kaya VC, Christoph Ruedig
$230M2021-03-02	Rohlik	Partech, Kaya VC, Omri Benayoun
$25M2019-09-30	Bnext	Redalpine, Speedinvest, Kaya VC
$—2019-05-14	Docplanner	Kaya VC
$—2017-12-14	Finiata	Point Nine Capital, Kaya VC, Kulczyk Investments, Fly Ventures, DNS Capital, Redalpine
$20M2016-06-07	Docplanner	Kaya VC
$12MUnknown date	Artificial Agency	Kaya VC
$9MUnknown date	SuperNova	Y Combinator, EQT Ventures, Kaya VC, Credo Ventures, J&T Ventures, Reflex Capital
$75M2026	Viktor	Accel, Kaya VC
$3MUnknown date	Riptides	Kaya VC

Funds1

Team

Co-investing

Investments